arrow
K

Katarzyna Jóźwiak

vrije universiteit amsterdam
H指数:29
被引数:2,760

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast Tumours

SPAG6的两面性:在乳腺肿瘤中SPAG6表达广泛缺失的背景下,诱导乳腺导管癌细胞发生EMT

2025-10-090
OAAI
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)

内分泌反应评估在HR阳性HER2阴性早期乳腺癌中的应用:WSG ADAPTcycle试验(n=5292)中局部与中央Ki67测量的符合情况

2025-08-140
OAAI
Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle Trial
2025-06-010
OA
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN
2025-02-140
OAAI
Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334)
2024-05-020
PRE
Circulating tumor DNA (ctDNA) for prediction of pathologic complete response (pCR) after 12 weeks of pembrolizumab plus trastuzumab plus pertuzumab in HER2-enriched early breast cancer: WSG-Keyriched-1 trial
2024-05-020
PRE
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer
2024-03-010
OAAI
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status

根据BRCA1状态的年轻,淋巴结阴性,化疗初治,三阴性乳腺癌患者的长期结果

2024-01-090
OAAI
The cumulative burden of self-reported, clinically relevant outcomes in long-term childhood cancer survivors and implications for survivorship care: A DCCSS LATER study

长期儿童癌症幸存者自我报告的临床相关结果的累积负担及其对生存护理的影响: DCCSS后期研究

CANCER
IF5.1
2023-12-153
PRE
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer

预测乳腺癌预后模型的外部验证和临床效用评估年轻,未经全身治疗的淋巴结阴性乳腺癌妇女

2023-12-010
OA
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2L early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2L trial
2023-06-012
PRE
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
2022-07-0715
OA